07.16.18
PCI Pharma Services has appointed Salim Haffar as chief executive officer. He will take the helm of the contract service provider later this year. Mr. Haffar resigned his current post as president of AptarGroup's Aptar Pharma, effective September 1, 2018, and will succeed Bill Mitchell. Mr. Mitchell will step out of his role as president and chief executive and assume the position of executive co-chairman.
"I am incredibly proud of what we have accomplished to date at PCI, and that is a credit to the entire team of talented employees with whom I have had the pleasure of working over the past six years," said Mr. Mitchell. "During that time, we have grown revenue from $85 million to $600 million, organically and through acquisitions. The past year has been one of especially strong performance, as we have completed two exciting acquisitions and achieved year-over-year growth of over 13 percent. As we continue to build on our strong
foundation and trajectory of success for the benefit of all our stakeholders, now is the right time to bring in a new chief executive who can take the baton and lead the management team in advancing PCI to the next level."
Mr. Haffar joins PCI with over 22 years of experience in the pharmaceutical industry, and currently serves as president of Aptar Pharma and a member of AptarGroup's senior executive committee. Mr. Haffar oversaw Aptar Pharma's growth strategy and journey to become a leading global provider of drug delivery systems across three end markets-prescription, consumer healthcare, and injectables-offering a broad portfolio of products and services, partnering with pharmaceutical customers to deliver medicines across several dosage forms and therapeutic areas, and operating across North America, Europe, Asia and Latin America.
"I am incredibly proud of what we have accomplished to date at PCI, and that is a credit to the entire team of talented employees with whom I have had the pleasure of working over the past six years," said Mr. Mitchell. "During that time, we have grown revenue from $85 million to $600 million, organically and through acquisitions. The past year has been one of especially strong performance, as we have completed two exciting acquisitions and achieved year-over-year growth of over 13 percent. As we continue to build on our strong
foundation and trajectory of success for the benefit of all our stakeholders, now is the right time to bring in a new chief executive who can take the baton and lead the management team in advancing PCI to the next level."
Mr. Haffar joins PCI with over 22 years of experience in the pharmaceutical industry, and currently serves as president of Aptar Pharma and a member of AptarGroup's senior executive committee. Mr. Haffar oversaw Aptar Pharma's growth strategy and journey to become a leading global provider of drug delivery systems across three end markets-prescription, consumer healthcare, and injectables-offering a broad portfolio of products and services, partnering with pharmaceutical customers to deliver medicines across several dosage forms and therapeutic areas, and operating across North America, Europe, Asia and Latin America.
